Scientists deliberately infect volunteers with omicron to study COVID-19

NCT ID NCT06492564

Completed Knowledge-focused Sponsor: Hvivo Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study involved 36 healthy adults aged 18 to 40 who were given a controlled dose of the Omicron BA.5 virus. The goal was to find a safe dose that causes infection in at least 40% of people, while monitoring side effects. This type of research helps scientists better understand the virus and could speed up development of new vaccines and treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SARS-CoV-2 Omicron BA.5 virus (live virus for controlled infection)
What this could lead to: If successful, this study could help researchers safely test new vaccines and treatments for COVID-19 using a controlled human infection model.
What could go wrong: This is a very early, small study (36 people) designed to understand the virus, not to treat or prevent disease. The results may not apply to the general population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARS-COV-2 INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARS-COV-2 INFECTION

Contacts and locations

Locations

hVIVO Services Ltd, 40 Bank Street, Canary Wharf

London, E14 5NR, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.